Biopharma companies still waiting for clarity on China’s new patent term extension regime
While all the focus has been on linkage, life sciences rights holders have unanswered questions about the final implementing regulations in another crucial area
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.